Article ID Journal Published Year Pages File Type
3370540 Journal of Clinical Virology 2008 7 Pages PDF
Abstract

BackgroundDetection of HBeAg and anti-HBe is valuable for the evaluation and therapeutic management of hepatitis B infection.ObjectivesTo determine the clinical performance of the newly CE-approveda HBeAg and anti-HBe assays on the fully automated, random access ADVIA Centaur® immunoassay system.Study designPatient samples collected at two sites were used to compare the ADVIA Centaur assays to Abbott AxSYM™ assays. Consensus of discordant results was reached using Roche Elecsys® assays. Additionally, two well-characterized seroconversion panels were evaluated.ResultsThe ADVIA Centaur HBeAg assay sensitivity was 100% and specificity was 99.5%. The ADVIA Centaur anti-HBe assay sensitivity was 100% and the resolved specificity was 98.2%. Fewer samples required retesting with the ADVIA Centaur assays than with the AxSYM. In two well-characterized seroconversion panels, the ADVIA Centaur anti-HBe assay detected anti-HBe 20–25 days earlier than the AxSYM assay; the ADVIA Centaur and AxSYM HBeAg assays detected HBe reactivity on the same day.ConclusionsThe ADVIA Centaur HBeAg and anti-HBe assays demonstrated good sensitivity and specificity, and thus are suitable for clinical use. Their novel algorithms require reduced retesting, suggesting these assays may be more cost effective.

Related Topics
Life Sciences Immunology and Microbiology Applied Microbiology and Biotechnology
Authors
, , , , , , , ,